A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

NCT04844918 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of tirzepatide, a medication, on body weight in adults with obesity.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 267 people

Who can join Ages 20+ · all sexes

Timeline Started 2021-05 · est. completion 2023-06

Where 18 sites · Japan

What this study is testing ClinicalTrials.gov NCT04844918 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Other

Administered SC

Main thing measured	Mean Percent Change in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04844918 ↗